🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — May 04, 2026

The IPO Pipeline stream features three S-1 filings dated May 4, 2026, dominated by dilutive resale registrations for Acurx Pharmaceuticals (two filings totaling ~2.95M shares) and a high-materiality SPAC IPO by Keystone Acquisition Corp ($250M base, up to $287.5M). No period-over-period financial trends (YoY/QoQ revenue/margins) are detailed, but pricing data reveals Acurx shares issued at low weighted average $3.07 post-Dec 2025 vs higher warrants ($7.25/$2.78), signaling share price pressure and funding desperation in biotech. Keystone's standard SPAC structure with founder shares at $0.003 highlights classic low-cost promotion potential. Overarching themes include biotech reliance on equity lines/warrants for working capital amid dilution risks (mixed/neutral sentiment), contrasted by resurgent SPAC activity. Critical implications: Acurx faces liquidity/price declines, while Keystone IPO could catalyze M&A hunting; portfolio-level pattern shows 2/3 filings as non-traditional 'IPOs' via resales, underscoring weak primary capital raise momentum.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — May 04, 2026

The 50 filings reveal a surge in high-priority events including positive insolvency resolutions (e.g., Embassy Developments quashing CIRP), a wave of IPO amendments in AI/tech/biotech (Cerebras, GMR Solutions, Fervo Energy), and active M&A/SPAC activity (GNL-Modiv merger, Blueport-SingAuto). Q1/FY2026 financials show mixed trends with average revenue growth of ~6-10% YoY across reporters (e.g., Berkshire +4.4%, Krystal +32%, National Vision +9%), but profitability volatile (Berkshire net earnings +119%, CNA -23%, Odyssey losses +15% YoY). Margin expansions in some (National Vision +520 bps) contrast compressions elsewhere, while capital returns include buybacks (Jagsonpal ₹40 Cr, Berkshire $235M treasury) and dividends. Indian filings highlight neutral board meetings and open offers amid insolvency risks, US-focused on IPOs/mergers with positive sentiment dominating (18/50 positive/mixed-positive). Portfolio-level: Industrials/real estate M&A bullish, biotech IPOs mixed on losses, no major insider selling patterns but leadership changes signal transitions. Implications: Near-term catalysts in earnings (May-Jun) and mergers offer alpha, watch delisting risks and trial readouts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 04, 2026

Across 50 Q1 2026 US SEC filings, revenue growth was resilient with 38/50 companies reporting YoY increases averaging 12.5% (range 0.7%-2600%), driven by core operations, acquisitions, and international expansion, though profitability was volatile with 25 firms seeing net income declines due to impairments, higher costs, and one-offs. Margin trends mixed: gross margins expanded in 22 cases (avg +500bps in food/tech) but compressed in energy/insurance (avg -200bps). Capital allocation robust with $15B+ in dividends/buybacks (e.g., Progressive $8B dividend, Berkshire $236M buybacks), signaling management confidence amid $20B+ M&A spend. Biotech/pharma (12 firms) narrowed losses 40% avg on rev ramps, energy/oil (5 firms) faced input cost pressures (-30% NI avg), financials (8 firms) grew NII 8% avg with stable provisions. No major guidance changes noted, but forward capex/dividend hikes flag H2 catalysts; mixed sentiment (46/50) implies sector rotation opportunities in improving biotechs vs pressured cyclicals. Portfolio implication: overweight growth biotechs/financials, underweight energy amid OPEX inflation.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 04, 2026

Both Hoth Therapeutics and Jaguar Health face severe Nasdaq delisting risks, with negative sentiment and high materiality (9-10/10), highlighting a pattern of compliance failures in the biotech sector on the Nasdaq Capital Market. Hoth received a bid price deficiency notice for 30 consecutive days below $1.00 (March 18-April 29, 2026), granting 180 days until October 27, 2026, to cure, while Jaguar, post a 1-for-35 reverse stock split on April 30, 2026, failed the 500,000 publicly held shares requirement (only 401,226 shares), adding to its bid price issues and triggering a May 8, 2026, response deadline to the Hearings Panel. No period-over-period financial trends, revenue growth, or margin data provided in filings, focusing purely on regulatory halts risks; no insider trading activity, capital allocation changes (beyond reverse split), or M&A noted. Cross-company comparison shows Jaguar's situation more acute (materiality 10/10 vs 9/10) due to recent reverse split failure, signaling portfolio-level distress in low-float biotechs. Market implications include potential trading suspensions, delistings, and heightened volatility, urging avoidance or short strategies for exposed positions.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 04, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, the dominant theme is proactive distress resolution through M&A (e.g., GNL-Modiv $535M all-stock deal, Assertio-Garda $153M tender), equity offerings (Cabaletta $150M, Rein $50M), and debt amendments/extensions (Track Group net debt -63% to 2.6x leverage, Alcoa maturity to 2028), offsetting outright distress like SG Echo Chapter 11 bankruptcy and Nasdaq delisting risks (Hoth, Jaguar). Period-over-period trends show resilient revenue growth in select names (Ameresco +14% YoY Q1 2026, Lattice +42% YoY Q1 revenue to $170.9M) but mixed profitability (Ameresco net loss widened to $18.3M YoY, Lattice op cash flow margin -10.1pp QoQ). Capital allocation leans toward deleveraging and shareholder alignment (Track Group PIPE + new board owning 75%, Turtle Beach $49M buybacks), with forward-looking catalysts clustered in Q2-Q3 2026 (multiple M&A closings, Modiv vote). Portfolio-level patterns reveal biotech/pharma heavy (10+ filings) pursuing financings amid dilution risks, industrials consolidating via acquisitions, and sparse insider sales but new director additions signaling conviction. Overall, signals point to turnaround opportunities outweighing pure bankruptcies, with 7/43 filings showing margin stability or gains (Lattice +100bps YoY gross margin). Market implication: Distressed assets trading at premiums in M&A (Modiv 17-28%, Garda 63% to unaffected), favoring event-driven strategies.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — May 04, 2026

Across 45 filings in the USA Executive & Director Changes stream (33 new), a wave of 20+ CEO/CFO/executive transitions dominates, including 8 retirements/planned departures (e.g., Publix Executive Chairman, Occidental CEO, Exxon CAO, Pool Corp CEO, Adeia CEO) and 15+ appointments/promotions (e.g., Aura CEO, Hercules President/CFO, Edwards Lifesciences CFO from Viatris), signaling proactive leadership refreshes amid sector pressures. Financial trends where reported show mixed results: BDCs like New Mountain (NII flat YoY at $0.32/share, NAV -5% QoQ to $10.92) and Great Elm (NII +13% QoQ to $0.36/share but NAV -4% QoQ to $7.74) highlight portfolio volatility; Sonos Q2 rev +8% YoY to $282M with first positive EBITDA in 4 years; Pinterest Q1 rev +18% YoY to $1.008B but net loss widened to $74M. Capital allocation remains shareholder-friendly with repurchases (New Mountain $66M YTD +$50M auth, Great Elm 1% shares at 36% NAV discount, Intuitive $5B program increase) and dividends (Great Elm $0.25/share Q2, 18% yield). Positive sentiments in 60% of filings (e.g., hires with deep expertise), but mixed/neutral in departures; biotech hires (Aura, Pasithea, Tivic) tie to trial catalysts. Portfolio-level: Margin stability in consumer/tech offset by BDC NAV erosion; energy/retail transitions orderly. Implications: Opportunities in growth-oriented hires (biotech, semis), risks in BDC volatility and sudden CFO churn (5 cases).

45 high priority 45 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 04, 2026

The single filing in the USA Bankruptcy & Insolvency stream highlights a major distress event for Olenox Industries Inc. (formerly Safe & Green Holdings Corp., SGBX), as its wholly-owned subsidiary SG Echo LLC filed voluntary Chapter 11 on April 28, 2026, in the Eastern District of Oklahoma, triggering a $4M loan default stay. No period-over-period financial trends are detailed, but the bankruptcy underscores underlying operational or liquidity pressures absent from prior disclosures. Parent company operations continue normally with the subsidiary operating as debtor-in-possession (DIP), suggesting contained impact but high materiality (10/10) and negative sentiment. Market implications include potential sharp equity downside, heightened volatility, and short-term trading opportunities in distressed assets. Portfolio-level pattern: isolated subsidiary restructuring amid broader insolvency watchlist, with no cross-filing comparisons available.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 04, 2026

Across 45 filings on USA Board Room Changes from May 4, 2026, a dominant theme is C-suite and board transitions, with 18 CEO/President/CFO changes (9 appointments, 9 departures/retirements), 12 new director additions, and 8 annual meetings showing strong shareholder approval (avg 95%+ for directors/say-on-pay). Period-over-period trends reveal mixed financial health: revenue growth in 4/7 reporters (Sonos +8% YoY Q2, Pinterest +18% YoY Q1 avg ARPU +6%, GECC NII +13% QoQ Q1, New Mountain NII flat YoY), but NAV declines in BDCs (GECC -4% QoQ to $7.74, New Mountain -5% to $10.92) and losses (Sonos Q2 GAAP net loss $29M improved YoY, Pinterest Q1 loss widened to $74M). Capital allocation remains shareholder-friendly with $5B Intuitive Surgical buyback increase, $2B Pinterest repurchases, GECC $57.5M note calls/$0.5M share buyback, New Mountain $66M YTD repurchases +$50M auth. Positive biotech appointments (Aura, Tivic, Pasithea) bolster trials, while planned energy transitions (Occidental, Exxon, Publix) signal continuity. Implications: Opportunities in experienced leadership hires amid churn, risks from interim roles and NAV pressure in BDCs/fintech.

45 high priority 45 total filings
· daily

US Merger & Acquisition SEC Filings — May 04, 2026

The 18 filings reveal a surge in US M&A and takeover activity dominated by SPAC IPOs, de-SPAC approvals, and completed acquisitions across sectors like logistics, defense/AI, beverages, biotech, banking, and homebuilding, with 6 new SPAC-related IPOs/pricings and 5 deal completions signaling robust dealmaking in May 2026. Positive sentiment prevails in 12/18 filings, driven by unanimous board approvals, large IPO sizes ($100M-$350M), and strategic acquisitions enhancing footprints (e.g., SunOpta delisting post-$6.50/share buyout, Gyre's $300M all-stock Cullgen deal). Key period trends include GBTG's Q1 revenue +35% YoY (7% ex-acqs) but margin contraction (-410 bps gross, -490 bps EBITDA) amid a pending acquisition; no broad insider selling/buying noted, but capital allocation favors trust deposits for SPAC extensions (e.g., $13.9K-$498 into trusts). Portfolio-level patterns show SPACs extending deadlines (3 cases) or approving mergers with low/no redemptions (e.g., Willow Lane $134.5M trust intact), contrasting one termination and Nasdaq compliance risks. Implications: heightened M&A liquidity for targets, but execution risks from redemptions (19.6M in AParadise) and regulatory hurdles; watch SPAC closings by Q3 2026 for de-SPAC catalysts.

18 high priority 18 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 04, 2026

Overnight SEC filings reveal a surge in IPO amendments (e.g., GMR Solutions, Cerebras, Odyssey Therapeutics, Liftoff Mobile, Fervo Energy) signaling robust capital market activity in AI, biotech, and EMS sectors, with proposed valuations from $205M to multi-billion enterprises amid positive sentiment. Earnings reports show mixed Q1 2026 results: revenue growth averaging +7% YoY across reporters (Berkshire +4.4%, National Vision +9%, Norwegian Cruise +10%, Illumina +4.8%), but net income volatility with Berkshire +119% outlier versus Loews -9%, CNA -23%, and margin compressions in insurance (CNA combined ratio 102.2% vs 98.4% YoY). M&A activity dominates industrials/REITs with Global Net Lease-Modiv $535M all-stock deal at 17% premium, immediately 4% AFFO accretive, alongside SPAC combos (Willow Lane-Boost Run, Blueport-SingAuto). Biotech catalysts abound with Cabaletta data presentations May 14 and Aura Phase 3 enrollment on track for H2 2027 topline. 13F filings indicate sustained institutional conviction in tech megacaps (NVIDIA, MSFT, AAPL top across multiple filers). Portfolio-level trends: Revenue resilience but insurance margin pressures (3/5 insurers combined ratio >100%), capital raises via IPOs/SPACs outpacing buybacks/dividends. Implications: Pre-market bullish for IPO/SPAC names and M&A targets, cautious on insurers/cruisers amid guidance cuts.

28 high priority 22 medium 50 total filings
· daily

DHS Homeland Security Contracts — May 02, 2026

A single DHS contract totaling $9,401,259 in obligations was analyzed, representing 100% civilian activity with zero defense-related components. The U.S. Coast Guard awarded Lockheed Martin Corporation a sole-source, cost-plus-fixed-fee contract for C4ISR integration and test laboratory services, spanning May 2022 to May 2027 in Moorestown, NJ. This neutral signal (strength 3/10, materiality 2/10) adds modestly to Lockheed Martin's federal IT services portfolio (NAICS 541513, PSC DC01), with estimated annual revenue of ~$1.88M. The highest-conviction signal is low materiality relative to Lockheed's scale, providing minimal sector impact. A key risk/watch item is zero funds outlayed to date despite $9.4M obligated, alongside $1.15M in unexercised options.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — May 02, 2026

The analyzed contracts total $269,952,453 in obligations, representing a 100% civilian split with zero defense-related awards, dominated by HHS's Office of Assistant Secretary for Preparedness and Response (ASPR) via BARDA Ventures. GLOBAL HEALTH INVESTMENT CORPORATION, a New York-based nonprofit, secured this $269,952,453 firm fixed price Definitive Contract on 2021-05-25 for health R&D (NAICS 541715, PSC AN41), with $241,937,500 (90%) already outlayed over the initial performance period from 2021-06-01 to 2031-06-01. The highest-conviction signal is neutral (4/10 strength), highlighting sustained federal funding for long-term health preparedness R&D but limited direct appeal for equity portfolios due to the recipient's nonprofit status. A key risk is high contract pricing risk under the firm fixed price structure within the BARDA Ventures Other Transaction Agreement. Watch outlay progress on the remaining ~$28 million obligation toward the 2031 current end date or potential extension to 2041.

1 total filings
· daily

New Federal Contractors — May 02, 2026

This digest synthesizes $1,718,415,049 in total obligations across 5 new civilian federal contracts (0/5 defense-related) awarded primarily to DOE, USDA, HHS, GSA, and DHS, highlighting civilian agency commitments to nuclear materials production, IT software/support, health R&D, financial services, and C4ISR lab services. Dominant sector themes include strategic nuclear capacity buildup via DOE's $900M award to ORANO FEDERAL SERVICES LLC and sustained IT investments like USDA's $294.6M Salesforce deal with CARAHSOFT TECHNOLOGY CORP. The highest-conviction bullish signal is CARAHSOFT TECHNOLOGY CORP's fully obligated and outlayed $294.6M USDA contract (strength 8/10), signaling reliable revenue through 2025. Balanced by neutral signals for nonprofit GLOBAL HEALTH INVESTMENT CORPORATION ($270M HHS) and modest LOCKHEED MARTIN ($9.4M DHS). Key risk: High pricing risk on firm-fixed-price structures across top awards (ORANO, CARAHSOFT, GLOBAL HEALTH), with watch on initial outlays post-May 2026 starts.

5 total filings
· daily

Significant Contract Modifications ($10M+) — May 02, 2026

This digest covers five significant civilian contract modifications totaling $1,718,415,049 in obligations, with 0/5 defense-related awards across DOE, USDA, HHS, GSA, and DHS. Dominant themes include strategic nuclear materials production (DOE/ORANO $900M) and IT/software services (USDA/Carahsoft $295M), underscoring civilian agency commitments to energy security and enterprise tech upgrades. Highest-conviction bullish signal is Carahsoft Technology Corp's fully obligated and outlayed $294.6M USDA Salesforce contract (strength 8/10), signaling reliable revenue through 2025. Key risk is high pricing risk on firm-fixed-price structures across top awards (ORANO, Carahsoft, GLOBAL HEALTH), with watch on initial outlays for ORANO's LEU production post-May 2026 start.

5 total filings
· daily

Contract Deobligations Alert — May 02, 2026

This Contract Deobligations Alert synthesizes $1,718,415,049 in total obligations across 5 civilian contracts (0 defense-related) awarded by DOE, USDA, HHS, GSA, and DHS, highlighting sustained federal commitments in nuclear materials, IT software, health R&D, financial services, and C4ISR support. Dominant themes include DOE's $900M push for domestic LEU production via ORANO FEDERAL SERVICES LLC and USDA's $294.6M Salesforce investment with CARAHSOFT TECHNOLOGY CORP, both full and open competition firm-fixed price awards. Highest-conviction signal is bullish for CARAHSOFT (strength 8/10, materiality 9/10) given full obligation and outlays on a 5-year USDA IT contract. Balanced by neutral signals for nonprofit GLOBAL HEALTH INVESTMENT CORPORATION ($270M HHS R&D) and small Lockheed Martin ($9.4M DHS) addition. Key risk: High pricing risk on firm-fixed structures across top contracts, with watch on initial outlays for ORANO post-May 2026 start.

5 total filings
· daily

Contract Option Exercises — May 02, 2026

This digest covers five civilian agency contract option exercises totaling $1,718,415,049 in obligations, with zero defense-related awards, highlighting sustained federal investment in nuclear materials, IT software, health R&D, financial services, and DHS IT support. Dominant themes include DOE's $900M commitment to domestic low-enriched uranium production via ORANO FEDERAL SERVICES LLC and USDA's fully outlayed $295M Salesforce deployment with CARAHSOFT TECHNOLOGY CORP, representing the highest-conviction bullish signals at 8/10 strength. BANK OF NEW YORK MELLON's $244M GSA financial services contract adds steady revenue visibility with $189M already outlayed. Neutral signals from GLOBAL HEALTH INVESTMENT CORPORATION's $270M HHS health R&D and Lockheed Martin's modest $9M DHS C4ISR lab services temper overall momentum. Key risk is high pricing risk across firm-fixed-price structures, with watch on initial outlays for ORANO post-May 2026 start and performance milestones to 2033.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — May 02, 2026

The single contract analyzed totals $294,589,912 in obligations, entirely civilian with zero defense exposure, centered on Department of Agriculture's enterprise-wide Salesforce software and support services via Carahsoft Technology Corp. This firm fixed-price delivery order, fully obligated and outlayed under full and open competition, provides a bullish signal for Carahsoft with high materiality (9/10) and strength (8/10), representing an estimated $58.9M in annual revenue through its 5-year performance period ending June 19, 2025. The dominant theme is USDA Office of the Chief Financial Officer's sustained IT modernization investment in NAICS 541519 and PSC 7030 categories. Highest-conviction signal is revenue visibility for Carahsoft in civilian federal IT reselling. Key watch item is the contract's performance end date of 2025-06-19 for potential follow-on opportunities amid high pricing execution risk.

1 total filings
· daily

All HHS Contracts — May 02, 2026

HHS awarded GLOBAL HEALTH INVESTMENT CORPORATION, a New York nonprofit, a single $269,952,453 firm fixed price contract under BARDA Ventures OTA for health R&D services (PSC AN41, NAICS 541715), representing a 0/1 defense/civilian split with full civilian focus via HHS/ASPR. With $241,937,500 (90%) already outlayed since the 2021-05-25 award, this underscores a dominant theme of long-term health preparedness R&D commitment through 2031-06-01 (potential 2041-06-01). The highest-conviction neutral signal (4/10 strength, 6/10 materiality) highlights sustained federal funding stability absent equity appeal. Key risk: high pricing risk under firm fixed price structure. Watch outlay progress on the remaining ~$28M obligation.

1 total filings
· daily

All DOE Contracts — May 02, 2026

The DOE awarded a single $900,000,000 firm fixed price delivery order to ORANO FEDERAL SERVICES LLC for establishing domestic low-enriched uranium (LEU) production capacity, representing full civilian exposure with zero defense-related contracts. This contract, managed by the DOE Idaho Operations Office under full and open competition, signals strong commitment to strategic nuclear materials over a 7-year period from May 1, 2026, to April 30, 2033. The highest-conviction bullish signal is ORANO FEDERAL SERVICES LLC's $900M obligation, estimating ~$128.6M annual revenue and bolstering the nuclear sector amid DOE priorities. Key risk includes high pricing risk due to firm fixed price structure, with investors watching initial outlays post-May 1, 2026, and LEU capacity milestones.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 02, 2026

Four civilian mega contracts totaling $1,709,013,790 in obligations highlight sustained federal commitments across DOE, USDA, HHS, and GSA, with zero defense-related awards. The dominant theme is strategic civilian investments, led by DOE's highest-materiality $900M award to ORANO FEDERAL SERVICES LLC for low-enriched uranium production. Highest-conviction bullish signal is CARAHSOFT TECHNOLOGY CORP's fully obligated and outlayed $294.6M USDA Salesforce contract (strength 8/10). Neutral signal from GLOBAL HEALTH INVESTMENT CORPORATION's $270M HHS health R&D award to a nonprofit limits direct equity upside. Key risk is high pricing risk on all firm-fixed-price structures; watch ORANO's initial outlays and LEU capacity milestones post-2026-05-01.

4 total filings